<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327184</url>
  </required_header>
  <id_info>
    <org_study_id>106388</org_study_id>
    <secondary_id>106390</secondary_id>
    <nct_id>NCT00327184</nct_id>
  </id_info>
  <brief_title>Primary &amp; Booster Study in Infants to Demonstrate Non-inferiority, Persistence &amp; Immunogenicity of Hib-MenC Vaccine</brief_title>
  <official_title>Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC Given With Infanrix™ Penta Versus NeisVac-C™ Given With Infanrix™ Hexa at 3, 5 Months of Age and Persistence Prior to a Hib-MenC Booster at 11 Months and Immunogenicity of the Booster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this primary vaccination phase is to demonstrate the non-inferiority of two
      doses of Biologicals' Hib-MenC conjugate vaccine when given with Infanrix™ penta to infants
      (at 3 &amp; 5m) compared to NeisVac-C™ given with Infanrix™ hexa.

      The purpose of the booster vaccination phase is to evaluate the immunogenicity, safety and
      reactogenicity of a booster dose of the Hib-MenC vaccine given with Infanrix™ penta at 11 m
      of age versus NeisVac-C™ given with Infanrix™ hexa, as well as the antibody persistence prior
      to the administration of the booster doses. The Protocol Posting has been updated in order to
      comply with the FDA Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study is open and consists of a primary and a booster phase. The study has 2
      treatment groups with NeisVac-C™ + Infanrix™ hexa as active controls. In the primary phase,
      one blood sample will be collected from all subjects for immunogenicity analyses- one month
      after the second vaccination dose. In the booster phase, two blood samples will be collected:
      prior to and one month post booster vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SBA-MenC titre</measure>
    <time_frame>One month after the second dose of the Primary Vaccination Phase.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-PRP concentration</measure>
    <time_frame>One month after the second dose of the Primary Vaccination Phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SBA-MenC titres</measure>
    <time_frame>One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP concentrations</measure>
    <time_frame>One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PSC concentrations</measure>
    <time_frame>One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs concentrations</measure>
    <time_frame>One month after the second dose of the Primary Vaccination Phase; prior to and one month after the Booster Vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of local solicited adverse events.</measure>
    <time_frame>During the solicited follow-up period (Day 0 - Day 3) following the administration of each vaccine dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited general adverse events</measure>
    <time_frame>During the solicited follow-up period (Day 0 - Day 3) following the administration of each vaccine dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited non-serious adverse events</measure>
    <time_frame>Within 30 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any serious adverse events</measure>
    <time_frame>Throughout the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">709</enrollment>
  <condition>Neisseria Meningitidis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>Group Hib-MenC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NeisVac-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)</intervention_name>
    <description>Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.</description>
    <arm_group_label>Group Hib-MenC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix Penta</intervention_name>
    <description>Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.</description>
    <arm_group_label>Group Hib-MenC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa</intervention_name>
    <description>Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age</description>
    <arm_group_label>Group NeisVac-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neis-Vac-C</intervention_name>
    <description>Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age</description>
    <arm_group_label>Group NeisVac-C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Primary Phase:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  healthy male or female subject between, and including, 6 and 12 weeks of age at the
             time of the first vaccination, born after a gestation period between and including 36
             and 42 weeks.

          -  Written informed consent obtained from the parent or guardian of the subject prior to
             the study entry.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

        Booster Phase:

        • Participation in primary phase of study.

        Exclusion Criteria

        Primary Phase:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) since birth or planned use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressant or other
             immune-modifying drugs since birth.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             since birth, with exception of BCG.

          -  Previous vaccination against meningococcal serogroup C disease, diphtheria, tetanus,
             pertussis, polio, pneumococcal, Hepatitis B or Hib disease

          -  History of Haemophilus influenzae type b and /or meningococcal serogroup C disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

        Additional Exclusion criteria for the Booster Phase:

        • Previous booster vaccination with Hib and/or MenC and/or DTP containing and/or IPV
        containing and/or HepB containing vaccine(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodi</city>
        <state>Lombardia</state>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ragusa</city>
        <state>Sicilia</state>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J. 2013 May;32(5):521-9. doi: 10.1097/INF.0b013e31827e22e3.</citation>
    <PMID>23190785</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>106388</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106388</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106388</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106388</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106388</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106388</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 106388 are summarised with study 106390 on the GSK Clinical Study Register.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

